Limitations:
This is a single centre experience and in spite of the collation of data over seven years, we could collect information from 32 patients. Large collaborative data sets would be necessary to throw light on this issue. The implications of various patterns of metastases on survival would have provided interesting insights but we were constrained by the fact that even with a long period of follow up, only five events were documented.
References
1. Ullmann TM, Gray KD, Moore MD, Zarnegar R, Fahey Iii TJ. Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.Gland Surgery. 2018;7(5):473-486.
2. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated Thyroid Cancer—Treatment: State of the Art. IJMS. 2017;18(6):1292.
3. McLeod DSA. Current Concepts and Future Directions in Differentiated Thyroid Cancer. Clin Biochem Rev. 2010;31(1):9-19.
4. Li F, Chen G, Sheng C, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.Endocrine-Related Cancer. 2015;22(2):159-168.
5. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians.2014;64(1):9-29.
6. Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. Journal of Clinical Investigation.2016;126(3):1052-1066.
7. Elshafie OT, Hussein S, Al-Hamdani A, Bererhi H, Woodhouse NJY. Multiple Bone Metastases in a Patient with Differentiated Thyroid Cancer (DTC). Sultan Qaboos Univ Med J.2010;10(1):101-105.
8. Wexler JA. Approach to the Thyroid Cancer Patient with Bone Metastases. The Journal of Clinical Endocrinology & Metabolism. 2011;96(8):2296-2307.
9. Lin J-D, Kuo S-F, Huang B-Y, Lin S-F, Chen S-T. The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis. Nucl Med Commun. 2018;39(12):1091-1096.
10. Singh Ospina N, Castro MR. Treatment of Recurrent/Metastatic Thyroid Cancer with Radioactive Iodine. In: Roman SA, Sosa JA, SolĂłrzano CC, eds. Management of Thyroid Nodules and Differentiated Thyroid Cancer: A Practical Guide.Cham: Springer International Publishing; 2017:315-329.
11. Kato S, Murakami H, Demura S, et al. The impact of complete surgical resection of spinal metastases on the survival of patients with thyroid cancer. Cancer Med.2016;5(9):2343-2349.
12. Kushchayeva YS, Kushchayev SV, Wexler JA, et al. Current Treatment Modalities for Spinal Metastases Secondary to Thyroid Carcinoma. Thyroid. 2014;24(10):1443-1455.
13. Durante C, Haddy N, Baudin E, et al. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy. The Journal of Clinical Endocrinology & Metabolism. 2006;91(8):2892-2899.
14. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 2008;37(2):511-524, xi.
15. Lee N, Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer.Endocrine-Related Cancer. 2006:971-977.
16. Kiess AP, Agrawal N, Brierley JD, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society.Head Neck. 2016;38(4):493-498.
17. Porterfield JR, Cassivi SD, Wigle DA, et al. Thoracic metastasectomy for thyroid malignancies.European Journal of Cardio-Thoracic Surgery. 2009;36(1):155-158.
18. Pitoia F, Bueno F, Cross G. Long-Term Survival and Low Effective Cumulative Radioiodine Doses to Achieve Remission in Patients With 131Iodine-Avid Lung Metastasis From Differentiated Thyroid Cancer. Clinical Nuclear Medicine.2014;39(9):784-790.
19. Ceccarelli C, Canale D, Vitti P. Radioactive iodine (131I) effects on male fertility. Current Opinion in Urology. 2008;18(6):598-601.
20. Turaka A, Li T, Yu JQ, et al. Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer.8.
21. Yarnold JR. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-upOn behalf of the Bone Pain Trial Working Party.Radiotherapy and Oncology. 1999;52(2):111-121.